Glenmark Pharmaceuticals Launches Potassium Phosphates Injection

The new product will provide a bioequivalent and affordable alternative to the reference drug.

Mar. 16, 2026 at 3:03pm

Got story updates? Submit your updates here. ›

Glenmark Pharmaceuticals Inc USA has announced the upcoming launch of 'Potassium Phosphates Injection USP', which will be available in 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi.

Why it matters

The launch of Glenmark's Potassium Phosphates Injection provides a new affordable and quality alternative for healthcare providers and patients in the US market, which recorded annual sales of about $50.7 million for the 12-month period ending January 2026.

The details

Glenmark's Potassium Phosphates Injection USP will be available in three formulations: 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. The company states that the product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi.

  • Glenmark will begin distribution of the new Potassium Phosphates Injection in March 2026.

The players

Glenmark Pharmaceuticals Inc USA

A pharmaceutical company that has announced the upcoming launch of Potassium Phosphates Injection USP.

Fresenius Kabi

The company that manufactures the reference listed drug for Potassium Phosphates Injection USP.

Got photos? Submit your photos here. ›

What they’re saying

“We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch.”

— Marc Kikuchi, President & Business Head, North America

The takeaway

The launch of Glenmark's Potassium Phosphates Injection provides a new affordable and bioequivalent option for healthcare providers and patients in the US market, helping to increase access to this important medication.